Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Net Income towards Common Stockholders of -$581000.0 for Q1 2026, up 25.13% year-over-year from -$464321.3 in Q1 2025, and up 29.06% quarter-over-quarter from -$819000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$581000.0 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 25.13% year-over-year to -$581000.0; the TTM figure through Mar 2026 stood at -$3.2 million (up 8.16% YoY), while the FY2026 annual figure was -$3.2 million, up 8.16% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$581000.0, up from -$819000.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$534000.0 in Q3 2025, with the low at -$1.9 million in Q4 2022.
- The 5-year median for Net Income towards Common Stockholders is -$972500.0 (2022), against an average of -$1.0 million.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders plunged 917.0% in 2022, then soared 58.89% in 2024.
- Sonoma Pharmaceuticals' Net Income towards Common Stockholders stood at -$1.9 million in 2022, then soared by 55.34% to -$866000.0 in 2023, then retreated by 7.16% to -$928000.0 in 2024, then grew by 11.75% to -$819000.0 in 2025, then increased by 29.06% to -$581000.0 in 2026.
- Business Quant data shows SNOA's Net Income towards Common Stockholders at -$581000.0 in Q1 2026, -$819000.0 in Q4 2025, and -$534000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.19 Mn | -145,899.91 | 2.58 Mn | -330,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -330,000.00 |
| Mar 31, 2026 | -581,000.00 |
| Dec 31, 2025 | -819,000.00 |
| Sep 30, 2025 | -534,000.00 |
| Jun 30, 2025 | -1.24 Mn |
| Mar 31, 2025 | -776,000.00 |
| Dec 31, 2024 | -928,000.00 |
| Sep 30, 2024 | -610,000.00 |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -866,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -1.42 Mn |
| Mar 31, 2023 | -1.31 Mn |
| Dec 31, 2022 | -1.94 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -887,000.00 |
| Sep 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -1.10 Mn |
| Mar 31, 2021 | -228,000.00 |